ArticleClinical and experimental vaccine research2024

Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.

Renan James Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.